Value proposition

Kallistem is a biotech company specialized in spermatogenesis. The company was founded in 2012 with the objective to anticipate and treat male infertility. It promotes a technology and expertise developed by Philippe Durand and Marie-Helene Perrard, two internationally renowned scientists in the field of the reproductive biology and more specially in in vitro spermatogenesis.

Kallistem has developed, in collaboration with its partners, original and innovating technologies of germinal cell culture for male fertility preservation and the treatment of male infertility.

male fertility, cellular therapy, biology of reproduction, and testicular toxicology